{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:05:10Z","timestamp":1791119110859,"version":"4.1.0"},"reference-count":184,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.mam.2009.08.006","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T04:31:40Z","timestamp":1251865900000},"page":"490-502","source":"Crossref","is-referenced-by-count":58,"title":["Anthrax vaccination strategies"],"prefix":"10.1016","volume":"30","author":[{"suffix":"Jr.","given":"Robert J.","family":"Cybulski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison D.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mam.2009.08.006_bib1","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/IAI.00261-07","article-title":"Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax","volume":"75","author":"Albrecht","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib2","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/IAI.73.7.4043-4053.2005","article-title":"Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen","volume":"73","author":"Aloni-Grinstein","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0014-5793(02)03609-8","article-title":"Anthrax toxin: a tripartite lethal combination","volume":"531","author":"Ascenzi","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.mam.2009.08.006_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.75.2.129","article-title":"Studies on immunity in anthrax. VI. Immunizing activity of protective antigen against various strains of Bacillus anthracis","volume":"75","author":"Auerbach","year":"1955","journal-title":"J. Immunol."},{"key":"10.1016\/j.mam.2009.08.006_bib5","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/IAI.73.6.3408-3414.2005","article-title":"Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines","volume":"73","author":"Aulinger","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/bsp.2006.0001","article-title":"Public health response to an anthrax attack: an evaluation of vaccination policy options","volume":"5","author":"Baccam","year":"2007","journal-title":"Biosecur. Bioterror."},{"key":"10.1016\/j.mam.2009.08.006_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2672.2001.01498.x","article-title":"The development of new vaccines against Bacillus anthracis","volume":"91","author":"Baillie","year":"2001","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0928-8244(03)00085-3","article-title":"Characterisation of the immune response to the UK human anthrax vaccine","volume":"36","author":"Baillie","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.femsim.2004.05.011","article-title":"Characterization of the human immune response to the UK anthrax vaccine","volume":"42","author":"Baillie","year":"2004","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib10","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1016\/j.vaccine.2008.09.010","article-title":"Towards a human oral vaccine for anthrax: the utility of a Salmonella typhi Ty21a-based prime-boost immunization strategy","volume":"26","author":"Baillie","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1128\/IAI.67.2.562-567.1999","article-title":"Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen","volume":"67","author":"Barnard","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib12","first-page":"385","article-title":"The development of anthrax following the administration of spores by inhalation","volume":"28","author":"Barnes","year":"1947","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.mam.2009.08.006_bib13","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1016\/S0264-410X(01)00197-9","article-title":"Passive transfer of protection against Bacillus anthracis infection in a murine model","volume":"19","author":"Beedham","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib14","first-page":"144","article-title":"Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production","volume":"35","author":"Belton","year":"1954","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.mam.2009.08.006_bib15","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/IAI.00070-07","article-title":"Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge","volume":"75","author":"Bielinska","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field evaluation of a human anthrax vaccine","volume":"52","author":"Brachman","year":"1962","journal-title":"Am. J. Public Health Nations Health"},{"key":"10.1016\/j.mam.2009.08.006_bib17","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1128\/IAI.00884-07","article-title":"Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen","volume":"75","author":"Brahmbhatt","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.addr.2005.01.028","article-title":"Molecular basis for improved anthrax vaccines","volume":"57","author":"Brey","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mam.2009.08.006_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/IAI.70.2.661-664.2002","article-title":"Anthrax spores make an essential contribution to vaccine efficacy","volume":"70","author":"Brossier","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib20","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1128\/IAI.68.4.1781-1786.2000","article-title":"Role of toxin functional domains in anthrax pathogenesis","volume":"68","author":"Brossier","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3201\/eid0808.010516","article-title":"Passive antibody administration (immediate immunity) as a specific defense against biological weapons","volume":"8","author":"Casadevall","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.mam.2009.08.006_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.vaccine.2004.05.029","article-title":"Anthrax capsule vaccine protects against experimental infection","volume":"23","author":"Chabot","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib24","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.vaccine.2003.11.064","article-title":"Pluronic F127-based systemic vaccine delivery systems","volume":"22","author":"Coeshott","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib25","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1128\/IAI.68.8.4549-4558.2000","article-title":"Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax","volume":"68","author":"Cohen","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib26","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1016\/j.vaccine.2008.07.015","article-title":"Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen","volume":"26","author":"Cybulski","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib27","first-page":"104","article-title":"Progress in the control and research of anthrax in China","volume":"68","author":"Dong","year":"1990","journal-title":"Salisb. Med. Bull."},{"key":"10.1016\/j.mam.2009.08.006_bib28","series-title":"Vaccine Adjuvants","first-page":"1","article-title":"An overview of adjuvant use","author":"Edelman","year":"2000"},{"key":"10.1016\/j.mam.2009.08.006_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1365-2672.1999.00881.x","article-title":"The capsule of Bacillus anthracis, a review","volume":"87","author":"Ezzell","year":"1999","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib30","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0264-410X(01)00021-4","article-title":"Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin","volume":"19","author":"Fellows","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib31","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/IAI.70.4.2022-2028.2002","article-title":"Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice","volume":"70","author":"Flick-Smith","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-142-8-200504190-00008","article-title":"Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax","volume":"142","author":"Fowler","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib33","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.282.22.2104","article-title":"Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax","volume":"282","author":"Friedlander","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.mam.2009.08.006_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"Friedlander","year":"1993","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.mam.2009.08.006_bib35","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1128\/IAI.72.12.7096-7106.2004","article-title":"Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA","volume":"72","author":"Galen","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib36","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.vaccine.2003.09.043","article-title":"Genetic immunization against anthrax","volume":"22","author":"Galloway","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib37","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1128\/IAI.71.7.3831-3836.2003","article-title":"Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge","volume":"71","author":"Garmory","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib38","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/S0264-410X(02)00207-4","article-title":"Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin","volume":"20","author":"Gaur","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib39","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1128\/IAI.01217-08","article-title":"Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax","volume":"77","author":"Gauthier","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib40","first-page":"217","article-title":"Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios","volume":"20","author":"Geier","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.mam.2009.08.006_bib41","first-page":"762","article-title":"Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the vaccine adverse events reporting system (VAERS) database","volume":"51","author":"Geier","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.mam.2009.08.006_bib42","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1462-5822.2006.00806.x","article-title":"Murine splenocytes produce inflammatory cytokines in a MyD88-dependent response to Bacillus anthracis spores","volume":"9","author":"Glomski","year":"2007","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/bi00866a036","article-title":"Immunochemical studies on the poly-g-d-glutamyl capsule of Bacillus anthracis. I. Characterization of the polypeptide and of the specificity of its reaction with rabbit antisera","volume":"5","author":"Goodman","year":"1966","journal-title":"Biochemistry"},{"key":"10.1016\/j.mam.2009.08.006_bib44","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/523578","article-title":"Vaccines: countering anthrax: vaccines and immunoglobulins","volume":"46","author":"Grabenstein","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.mam.2009.08.006_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/epirev\/mxj003","article-title":"Immunization to protect the US Armed Forces: heritage, current practice, and prospects","volume":"28","author":"Grabenstein","year":"2006","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.mam.2009.08.006_bib47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/milmed\/167.1.74","article-title":"Delayed-type hypersensitivity reaction to anthrax vaccine","volume":"167","author":"Greidanus","year":"2002","journal-title":"Mil. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0264-410X(98)00210-2","article-title":"Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen","volume":"17","author":"Gu","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib49","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/JB.91.6.2382-2384.1966","article-title":"Fine filaments on the outside of the exosporium of Bacillus anthracis spores","volume":"91","author":"Hachisuka","year":"1966","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.mam.2009.08.006_bib50","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1016\/j.vaccine.2005.08.031","article-title":"DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components","volume":"24","author":"Hahn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib51","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1016\/j.vaccine.2005.08.025","article-title":"Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep","volume":"24","author":"Hahn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0264-410X(84)90003-3","article-title":"Anthrax: the disease in relation to vaccines","volume":"2","author":"Hambleton","year":"1984","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib53","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/infdis\/160.4.706","article-title":"Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay","volume":"160","author":"Harrison","year":"1989","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.mam.2009.08.006_bib54","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1128\/IAI.73.10.6885-6891.2005","article-title":"Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity","volume":"73","author":"Hashimoto","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey","volume":"54","author":"Henderson","year":"1956","journal-title":"J. Hyg."},{"key":"10.1016\/j.mam.2009.08.006_bib56","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.vaccine.2005.10.018","article-title":"A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection","volume":"24","author":"Hepler","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib57","doi-asserted-by":"crossref","first-page":"13601","DOI":"10.1073\/pnas.0405557101","article-title":"A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores","volume":"101","author":"Hermanson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mam.2009.08.006_bib58","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2008.05.068","article-title":"An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals","volume":"26","author":"Hewetson","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib59","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1016\/S0264-410X(03)00435-3","article-title":"Using a structured medical note for determining the safety profile of anthrax vaccine for US soldiers in Korea","volume":"21","author":"Hoffman","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.3.3.4011","article-title":"Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge","volume":"3","author":"Huang","year":"2007","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib61","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7205\/MILMED.169.10.833","article-title":"Health effects of anthrax vaccination in the Canadian forces","volume":"169","author":"Hunter","year":"2004","journal-title":"Mil. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib62","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0264-410X(95)00139-R","article-title":"Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs","volume":"13","author":"Ivins","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib63","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/IAI.52.2.454-458.1986","article-title":"Immunization studies with attenuated strains of Bacillus anthracis","volume":"52","author":"Ivins","year":"1986","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib64","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/IAI.58.2.303-308.1990","article-title":"Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen","volume":"58","author":"Ivins","year":"1990","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib66","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1128\/IAI.60.2.662-668.1992","article-title":"Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants","volume":"60","author":"Ivins","year":"1992","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib67","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg. Infect. Dis"},{"key":"10.1016\/j.mam.2009.08.006_bib68","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.mam.2009.08.006_bib69","series-title":"The Anthrax Vaccine: Is It Safe? Does It Work?","author":"Joellenbeck","year":"2002"},{"key":"10.1016\/j.mam.2009.08.006_bib70","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1074\/jbc.M509432200","article-title":"Immunogenicity and protective efficacy of Bacillus anthracis poly-g-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy","volume":"281","author":"Joyce","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2009.08.006_bib71","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14760584.5.4.417","article-title":"Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine","volume":"5","author":"Keitel","year":"2006","journal-title":"Expert Rev. Vaccines."},{"key":"10.1016\/j.mam.2009.08.006_bib72","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/422694","article-title":"Induction of protective immunity against lethal anthrax challenge with a patch","volume":"190","author":"Kenney","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.mam.2009.08.006_bib73","first-page":"315","article-title":"The chemical basis of the virulence of Bacillus anthracis. III. The role of the terminal bacteraemia in death of guinea-pigs from anthrax","volume":"36","author":"Keppie","year":"1955","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.mam.2009.08.006_bib74","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1016\/j.vaccine.2008.07.062","article-title":"A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge","volume":"26","author":"Klas","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4049\/jimmunol.88.1.15","article-title":"Immunological studies of anthrox. II. Levels of immunity against Bacillus anthracis obtained with protective antigen and live vaccine","volume":"88","author":"Klein","year":"1962","journal-title":"J. Immunol."},{"key":"10.1016\/j.mam.2009.08.006_bib76","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","article-title":"CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques","volume":"22","author":"Klinman","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib77","first-page":"1040","article-title":"Protective antigen composite nanofibers as a transdermal anthrax vaccine","volume":"1","author":"Knockenhauer","year":"2008","journal-title":"Conf. Proc. IEEE Eng. Med. Biol. Soc."},{"key":"10.1016\/j.mam.2009.08.006_bib78","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/IAI.70.2.544-550.2002","article-title":"Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization","volume":"70","author":"Kobiler","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib79","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1073\/pnas.0401351101","article-title":"MAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia","volume":"101","author":"Kozel","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mam.2009.08.006_bib80","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/IAI.01133-06","article-title":"Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule","volume":"75","author":"Kozel","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib81","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0264-410X(02)00723-5","article-title":"Comprehensive systematic surveillance for adverse effects of anthrax vaccine adsorbed, US Armed Forces, 1998\u20132000","volume":"21","author":"Lange","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib82","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/IAI.71.3.1491-1496.2003","article-title":"Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge","volume":"71","author":"Lee","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00063030-200519040-00003","article-title":"Anthrax vaccines: a development update","volume":"19","author":"Little","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.mam.2009.08.006_bib84","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/IAI.65.12.5171-5175.1997","article-title":"Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs","volume":"65","author":"Little","year":"1997","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib85","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib86","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2005.12.028","article-title":"Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine","volume":"24","author":"Little","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib87","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1128\/IAI.52.2.509-512.1986","article-title":"Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig","volume":"52","author":"Little","year":"1986","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib88","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/mt.2008.242","article-title":"Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors","volume":"17","author":"Liu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mam.2009.08.006_bib89","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1016\/j.vaccine.2008.03.064","article-title":"Potentiation of an anthrax DNA vaccine with electroporation","volume":"26","author":"Luxembourg","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib90","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1128\/IAI.73.12.8362-8368.2005","article-title":"Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region","volume":"73","author":"Mabry","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib91","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.mam.2009.08.006_bib92","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/IAI.72.6.3471-3477.2004","article-title":"Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine","volume":"72","author":"Marcus","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib93","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1128\/IAI.72.2.1181-1183.2004","article-title":"Needle-free skin patch vaccination method for anthrax","volume":"72","author":"Matyas","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib94","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0264-410X(97)00268-5","article-title":"Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers","volume":"16","author":"McBride","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib95","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/pds.1359","article-title":"Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967\u20131972 study and review of the 1955\u20132005 medical literature","volume":"16","author":"McNeil","year":"2007","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"10.1016\/j.mam.2009.08.006_bib96","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1016\/j.vaccine.2004.11.077","article-title":"Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components","volume":"23","author":"Mendelson","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib97","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/eji.200838058","article-title":"Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses","volume":"39","author":"Midha","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.mam.2009.08.006_bib98","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1128\/IAI.01210-06","article-title":"Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine","volume":"74","author":"Mikszta","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib99","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1086\/426865","article-title":"Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms","volume":"191","author":"Mikszta","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.mam.2009.08.006_bib100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev.micro.55.1.647","article-title":"Anthrax","volume":"55","author":"Mock","year":"2001","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib101","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/14760584.7.2.163","article-title":"Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria","volume":"7","author":"Mohamadzadeh","year":"2008","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.mam.2009.08.006_bib102","doi-asserted-by":"crossref","unstructured":"Mohamadzadeh, M., Duong, T., Sandwick, S.J., Hoover, T., Klaenhammer, T.R., 2009. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. USA","DOI":"10.1073\/pnas.0900029106"},{"key":"10.1016\/j.mam.2009.08.006_bib103","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","article-title":"A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge","volume":"73","author":"Mohamed","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib104","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1128\/IAI.72.6.3276-3283.2004","article-title":"Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages","volume":"72","author":"Mohamed","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3181\/00379727-114-28656","article-title":"Alterations in the biological activity of protective antigen of Bacillus anthracis toxin","volume":"114","author":"Molnar","year":"1963","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib106","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2180-8-159","article-title":"Passive administration of monoclonal antibodies to anthrolysin O prolong survival in mice lethally infected with Bacillus anthracis","volume":"8","author":"Nakouzi","year":"2008","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0891-5520(05)70050-7","article-title":"Anthrax vaccine. Model of a response to the biologic warfare threat","volume":"13","author":"Nass","year":"1999","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.mam.2009.08.006_bib108","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.vaccine.2008.10.044","article-title":"Adverse events after anthrax vaccination reported to the vaccine adverse event reporting system (VAERS), 1990\u20132007","volume":"27","author":"Niu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib109","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/IAI.00828-08","article-title":"Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge","volume":"77","author":"Osorio","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/pds.1213","article-title":"Development of the Vaccine Analytic Unit\u2019s research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed","volume":"16","author":"Payne","year":"2007","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"10.1016\/j.mam.2009.08.006_bib111","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1128\/IAI.74.1.794-797.2006","article-title":"Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen","volume":"74","author":"Peachman","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib112","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1128\/AAC.01528-06","article-title":"High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation","volume":"51","author":"Pelat","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mam.2009.08.006_bib113","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1128\/IAI.00352-07","article-title":"Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model","volume":"75","author":"Peterson","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib114","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/IAI.74.2.1016-1024.2006","article-title":"Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax","volume":"74","author":"Peterson","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib115","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1128\/IAI.59.10.3472-3477.1991","article-title":"Contribution of individual toxin components to virulence of Bacillus anthracis","volume":"59","author":"Pezard","year":"1991","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib116","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/IAI.63.4.1369-1372.1995","article-title":"Protective immunity induced by Bacillus anthracis toxin-deficient strains","volume":"63","author":"Pezard","year":"1995","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib117","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2672.1999.00897.x","article-title":"In vitro correlate of immunity in an animal model of inhalational anthrax","volume":"87","author":"Pitt","year":"1999","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib118","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib119","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.vaccine.2004.06.026","article-title":"Long-term health effects of repeated exposure to multiple vaccines","volume":"23","author":"Pittman","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib120","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib121","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib122","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CDLI.12.6.713-721.2005","article-title":"Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis","volume":"12","author":"Pittman","year":"2005","journal-title":"Clin. Diagn. Lab Immunol."},{"key":"10.1016\/j.mam.2009.08.006_bib123","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0264-410X(00)00174-2","article-title":"Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans","volume":"19","author":"Pittman","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib124","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1016\/j.vaccine.2006.01.054","article-title":"Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series","volume":"24","author":"Pittman","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib125","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1128\/IAI.69.7.4509-4515.2001","article-title":"Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein","volume":"69","author":"Price","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib126","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1128\/JB.68.4.474-482.1954","article-title":"Studies on immunity in anthrax. IV. Factors influencing elaboration of the protective antigen of Bacillus anthracis in chemically defined media","author":"Puziss","year":"1954","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.mam.2009.08.006_bib127","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.jim.7000239","article-title":"Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis","volume":"28","author":"Ramirez","year":"2002","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"10.1016\/j.mam.2009.08.006_bib128","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.femsim.2005.05.009","article-title":"Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis","volume":"45","author":"Rhie","year":"2005","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib130","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1073\/pnas.1834478100","article-title":"A dually active anthrax vaccine that confers protection against both bacilli and toxins","volume":"100","author":"Rhie","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mam.2009.08.006_bib131","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/IAI.00275-06","article-title":"Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival","volume":"74","author":"Ribot","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib132","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1016\/S0264-410X(03)00362-1","article-title":"Comparison of individual and combination DNA vaccines for B. Anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus","volume":"21","author":"Riemenschneider","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib133","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-2-5","article-title":"Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed","volume":"2","author":"Sawada-Hirai","year":"2004","journal-title":"J. Immune Based Ther. Vaccines"},{"key":"10.1016\/j.mam.2009.08.006_bib134","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1073\/pnas.1633512100","article-title":"Poly(gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine","volume":"100","author":"Schneerson","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mam.2009.08.006_bib135","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1126\/science.109563","article-title":"Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax","volume":"292","author":"Sellman","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.mam.2009.08.006_bib136","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1074\/jbc.M008309200","article-title":"Point mutations in anthrax protective antigen that block translocation","volume":"276","author":"Sellman","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2009.08.006_bib137","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pds.936","article-title":"Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the vaccine adverse event reporting system (VAERS)","volume":"13","author":"Sever","year":"2004","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"10.1016\/j.mam.2009.08.006_bib138","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2006.10.010","article-title":"Multicomponent anthrax toxin display and delivery using bacteriophage T4","volume":"25","author":"Shivachandra","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib139","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0264-410X(94)90223-2","article-title":"Human live anthrax vaccine in the former USSR","volume":"12","author":"Shlyakhov","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib140","first-page":"869","article-title":"Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among US","volume":"26","author":"Singer","year":"2008","journal-title":"Mil. Personnel. Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib141","doi-asserted-by":"crossref","first-page":"22090","DOI":"10.1074\/jbc.M010222200","article-title":"A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo","volume":"276","author":"Singh","year":"2001","journal-title":"J Biol. Chem."},{"key":"10.1016\/j.mam.2009.08.006_bib142","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4269\/ajtmh.1988.39.575","article-title":"Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand","volume":"39","author":"Sirisanthana","year":"1988","journal-title":"Am. J Trop. Med. Hyg."},{"key":"10.1016\/j.mam.2009.08.006_bib143","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/IAI.00530-08","article-title":"Killed but metabolically active bacillus anthracis vaccines induce broad and protective immunity against anthrax","volume":"77","author":"Skoble","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib144","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1016\/j.vaccine.2006.06.002","article-title":"Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli","volume":"24","author":"Sloat","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib145","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s11095-006-0206-9","article-title":"Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities","volume":"23","author":"Sloat","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.mam.2009.08.006_bib146","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.amepre.2006.12.015","article-title":"Anthrax vaccination in the Millennium Cohort: validation and measures of health","volume":"32","author":"Smith","year":"2007","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib147","first-page":"460","article-title":"The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. Anthracis in vivo","volume":"36","author":"Smith","year":"1955","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.mam.2009.08.006_bib148","first-page":"323","article-title":"The chemical basis of the virulence of Bacillus anthracis. IV. Secondary shock as the major factor in death of guinea-pigs from anthrax","volume":"36","author":"Smith","year":"1955","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.mam.2009.08.006_bib149","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/IAI.00529-07","article-title":"In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity","volume":"75","author":"Staats","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib150","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1128\/JB.187.17.5868-5876.2005","article-title":"Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis","volume":"187","author":"Steichen","year":"2005","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.mam.2009.08.006_bib151","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0736-4679(03)00079-9","article-title":"The history of anthrax","volume":"24","author":"Sternbach","year":"2003","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib152","first-page":"307","article-title":"The use of anthrax vaccines prepared from avirulent (uncapsulated) variants of Bacillus anthracis","volume":"13","author":"Sterne","year":"1939","journal-title":"Onderstepoort J. Vet. Sci. Anim. Ind."},{"key":"10.1016\/j.mam.2009.08.006_bib153","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1128\/IAI.01242-06","article-title":"Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis","volume":"75","author":"Stokes","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib154","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1081\/CLT-100102885","article-title":"Delayed life-threatening reaction to anthrax vaccine","volume":"39","author":"Swanson-Biearman","year":"2001","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.mam.2009.08.006_bib155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2958.2000.03000.x","article-title":"A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium","volume":"45","author":"Sylvestre","year":"2002","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib156","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.smim.2003.10.009","article-title":"Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9","volume":"16","author":"Takeshita","year":"2004","journal-title":"Semin. Immunol"},{"key":"10.1016\/j.mam.2009.08.006_bib157","unstructured":"The Jackson Laboratory, 2008. A\/J Strain Information Page. <http:\/\/jaxmice.jax.org\/strain\/000646.html>."},{"key":"10.1016\/j.mam.2009.08.006_bib158","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S0022172400063488","article-title":"Anthrax. William Smith Greenfield, M.D., F.R.C.P., professor superintendent, the Brown Animal Sanatory Institution (1878\u201381) concerning the priority due to him for the production of the first vaccine against anthrax","volume":"85","author":"Tigertt","year":"1980","journal-title":"J. Hyg. (Lond.)"},{"key":"10.1016\/j.mam.2009.08.006_bib159","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14787210.7.2.219","article-title":"Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis","volume":"7","author":"Tournier","year":"2009","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"10.1016\/j.mam.2009.08.006_bib160","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0264-410X(91)90237-Z","article-title":"Anthrax vaccines: past, present and future","volume":"9","author":"Turnbull","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib161","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00001432-200004000-00004","article-title":"Current status of immunization against anthrax: old vaccines may be here to stay for a while","volume":"13","author":"Turnbull","year":"2000","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.mam.2009.08.006_bib162","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00189414","article-title":"Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"177","author":"Turnbull","year":"1988","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.mam.2009.08.006_bib163","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1081-1206(10)61379-8","article-title":"New-onset rheumatoid arthritis after anthrax vaccination","volume":"97","author":"Vasudev","year":"2006","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.mam.2009.08.006_bib164","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-9433-4-4","article-title":"Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin","volume":"4","author":"Wang","year":"2005","journal-title":"Med. Immunol."},{"key":"10.1016\/j.mam.2009.08.006_bib165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0928-8244(03)00366-3","article-title":"Induction of opsonic antibodies to the g-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate","volume":"40","author":"Wang","year":"2004","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib166","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.jom.0000058345.05741.6b","article-title":"Analysis of adverse events after anthrax immunization in US Army medical personnel","volume":"45","author":"Wasserman","year":"2003","journal-title":"J. Occup. Environ. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib167","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/IAI.74.1.394-398.2006","article-title":"Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits","volume":"74","author":"Weiss","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib168","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/0022-1317-51-10-821","article-title":"In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody","volume":"51","author":"Welkos","year":"2002","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib169","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"key":"10.1016\/j.mam.2009.08.006_bib170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0882-4010(88)90015-0","article-title":"Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice","volume":"5","author":"Welkos","year":"1988","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.mam.2009.08.006_bib171","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0882-4010(88)90048-4","article-title":"Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis","volume":"4","author":"Welkos","year":"1988","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.mam.2009.08.006_bib172","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1016\/j.vaccine.2004.04.036","article-title":"Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis","volume":"22","author":"Whiting","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib173","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3233\/HAB-2007-163-404","article-title":"A human antibody against anthrax protective antigen protects rabbits from lethal infection with aerosolized spores","volume":"16","author":"Wild","year":"2007","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.mam.2009.08.006_bib174","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nbt891","article-title":"Human antibodies from immunized donors are protective against anthrax toxin in vivo","volume":"21","author":"Wild","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mam.2009.08.006_bib175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2672.1999.00901.x","article-title":"Presentation of protective antigen to the mouse immune system: immune sequelae","volume":"87","author":"Williamson","year":"1999","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.mam.2009.08.006_bib176","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1128\/IAI.73.9.5978-5987.2005","article-title":"Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.mam.2009.08.006_bib177","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1016\/j.vaccine.2006.02.024","article-title":"An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits","volume":"24","author":"Wimer-Mackin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib178","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4049\/jimmunol.72.4.263","article-title":"Studies on immunity in anthrax. III. Elaboration of protective antigen in a chemically defined, non-protein medium","volume":"72","author":"Wright","year":"1954","journal-title":"J. Immunol."},{"key":"10.1016\/j.mam.2009.08.006_bib179","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1084\/jem.93.6.523","article-title":"Studies on immunity in anthrax. II. In vitro elaboration of protective antigen by non-proteolytic mutants of Bacillus anthracis","volume":"93","author":"Wright","year":"1951","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.93.2.99","article-title":"Studies on immunity in anthrax. I. Variation in the serum T-agglutinin during anthrax infection in the rabbit","volume":"93","author":"Wright","year":"1951","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.mam.2009.08.006_bib181","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.vaccine.2007.11.087","article-title":"Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates","volume":"26","author":"Yan","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib182","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1016\/j.vaccine.2007.01.075","article-title":"Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine","volume":"25","author":"Zeng","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib183","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.vaccine.2007.11.072","article-title":"Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses","volume":"26","author":"Zhang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2009.08.006_bib184","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.bmc.2007.11.001","article-title":"Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin","volume":"16","author":"Zhou","year":"2008","journal-title":"Bioorg. Med. Chem."}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299709000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299709000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:34:41Z","timestamp":1685100881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299709000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":184,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0098299709000582"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2009.08.006","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}